[] SeouLin Bioscience Co. Ltd., invests in overseas new drug development company for cancer vaccine
2020-03-18
SeouLin Bioscience Co. Ltd., invests in overseas new drug development company for cancer vaccine
On March 18, SeouLin Bioscience announced that it will invest $ 3.6 million in XEME Biopharma (below XEME), a new drug development company for cancer vaccine located in Illinois US.
Since its founding in 2005, XEME has been recognized for its unique cancer vaccine platform by the National Cancer Center and the US Food and Drug Administration (FDA) for 15 years. Currently in Phase 2 clinical trials. XEME explained that it has developed a unique platform for a personalized cancer treatment vaccine that uses its entire cancer cell as an antigen, which is also available for treatment and prevention of blood cancer, solid cancer and coronavirus in parallel with existing immuno-cancer drugs and latest anti-cancer treatments.
With the agreement, SeouLin Bioscience signed a memorandum of understanding(MOU) with XEME’s parent company, R2T. Through the signing of the MOU, the two companies agreed to actively cooperate for the marketing and distribution of XEME's cancer vaccine technology and the sale of R2T's unique dry treatment formula.
Through these contracts, we want to advance into the market for cancer vaccines and immunotherapy products for treatment, equip ourselves with new momentum, and contribute to improving human health and quality of life, said Eul-moon, Hwang, CEO of SeouLin Bioscience.
On March 18, SeouLin Bioscience announced that it will invest $ 3.6 million in XEME Biopharma (below XEME), a new drug development company for cancer vaccine located in Illinois US.
Since its founding in 2005, XEME has been recognized for its unique cancer vaccine platform by the National Cancer Center and the US Food and Drug Administration (FDA) for 15 years. Currently in Phase 2 clinical trials. XEME explained that it has developed a unique platform for a personalized cancer treatment vaccine that uses its entire cancer cell as an antigen, which is also available for treatment and prevention of blood cancer, solid cancer and coronavirus in parallel with existing immuno-cancer drugs and latest anti-cancer treatments.
With the agreement, SeouLin Bioscience signed a memorandum of understanding(MOU) with XEME’s parent company, R2T. Through the signing of the MOU, the two companies agreed to actively cooperate for the marketing and distribution of XEME's cancer vaccine technology and the sale of R2T's unique dry treatment formula.
Through these contracts, we want to advance into the market for cancer vaccines and immunotherapy products for treatment, equip ourselves with new momentum, and contribute to improving human health and quality of life, said Eul-moon, Hwang, CEO of SeouLin Bioscience.
